L’intolérance musculaire aux statines

Boulanger‐Piette, Antoine; Bergeron, Jean; Desgreniers, Joël; Côté-Levesque, Michèle; Brassard, Dominic; Joanisse, Denis R.; Frenette, Jérôme

doi:10.1051/medsci/20153112014

Cited by 4 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Statins are effective for the primary and secondary prevention of cardiovascular diseases, but their use is frequently associated with statin-induced myopathy (SIM). SIM encompasses myalgia, cramps, weakness, and even rhabdomyolysis [1–3]. While the pathophysiology of SIM is heterogeneous and poorly understood, it appears to be multifactorial and may involve multiple pathophysiological defects, including genetic predisposition [4], early mitochondrial dysfunctions [5–8], prenylated proteins [9], the inhibition of protein geranylgeranylation [10], ubiquinone depletion [11, 12], monocarboxylate transporter 4 expression [13, 14], loss of t-tubular region architecture [15, 16], altered membrane fluidity [17], and immune-mediated necrotis [18].…”

Section: Introductionmentioning

confidence: 99%

A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles

Piette

Dufresne

Frenette

2016

BMC Musculoskelet Disord

Self Cite

View full text Add to dashboard Cite

BackgroundCumulative evidence indicates that statins induce myotoxicity. However, the lack of understanding of how statins affect skeletal muscles at the structural, functional, and physiological levels hampers proper healthcare management. The purpose of the present study was to investigate the early after-effects of lovastatin on the slow-twitch soleus (Sol) and fast-twitch extensor digitorum longus (EDL) muscles.MethodsAdult C57BL/6 mice were orally administrated with placebo or lovastatin [50 mg/kg/d] for 28 days. At the end of the treatment, the isometric ex vivo contractile properties of the Sol and EDL muscles were measured. Subtetanic and tetanic contractions were assessed and contraction kinetics were recorded. The muscles were then frozen for immunohistochemical analyses. Data were analyzed by two-way ANOVA followed by an a posteriori Tukey’s test.ResultsThe short-term lovastatin treatment did not induce muscle mass loss, muscle fiber atrophy, or creatine kinase (CK) release. It had no functional impact on slow-twitch Sol muscles. However, subtetanic stimulations at 10 Hz provoked greater force production in fast-twitch EDL muscles. The treatment also decreased the maximal rate of force development (dP/dT) of twitch contractions and prolonged the half relaxation time (1/2RT) of tetanic contractions of EDL muscles.ConclusionsAn early short-term statin treatment induced subtle but significant changes in some parameters of the contractile profile of EDL muscles, providing new insights into the selective initiation of statin-induced myopathy in fast-twitch muscles.

show abstract

Section: Introductionmentioning

confidence: 99%

A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles

Piette

Dufresne

Frenette

2016

BMC Musculoskelet Disord

Self Cite

View full text Add to dashboard Cite

show abstract

“…Statins are now used by over 200 million people around the world (2), but controversies remain on the nature and prevalence of their side effects. These effects can include the development of diabetes, elevated circulating liver enzymes and joint pain (3,4), but statinassociated muscle symptoms (SAMS) are the most frequently reported side effects of statin use. Mild myalgia has often been reported by 5-10% of statin users (4,5), this rate reaching around 20% in a few reports (6,7).…”

Section: Introductionmentioning

confidence: 99%

Impact of statin withdrawal on perceived and objective muscle function

Peyrel

Mauriège

Frenette

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background and Aims: Statin-associated muscle symptoms (SAMS) are frequently reported. Nevertheless, few data on objective measures of muscle function are available. Recent data suggesting an important nocebo effect with statin use could confound such effects. The objective was to assess if subjective and objective measures of muscle function improve after drug withdrawal in SAMS reporters. Methods: Patients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention composed three cohorts: statin users with (SAMS, n=61) or without symptoms (No SAMS, n=15), and controls (n=16). Force (FO), endurance (EN) and power (PO) of the leg extensors (EXT) and flexors (FLE) and handgrip strength (FOHG) were measured using isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale (VAS) was used to self-assess SAMS intensity. Measures were taken before and after two months of withdrawal. Results: Following withdrawal, repeated-measures analyses show improvements for the entire cohort in ENEXT, ENFLE, FOFLE, POEXT and POFLE (range +7.2 to +13.3%, all p≤0.02). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to +16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS, from 5.09 to 1.85). FOHG was also improved in SAMS (+4.0 to +6.2%) when compared to No SAMS (-1.7 to -4.2%) (all p=0.02). Conclusions: Whether suffering from “true” SAMS or nocebo, those who reported SAMS had modest but relevant improvements in muscle function concurrent with a decrease in subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to muscle function in frail statin users appears warranted.

show abstract

“…Statins are now used by over 200 million people around the world [ 2 ], but controversies remain on the nature and prevalence of their side effects. These effects can include the development of diabetes, elevated circulating liver enzymes and joint pain [ 3 , 4 ], but statin-associated muscle symptoms (SAMS) are the most frequently reported side effects of statin use. Mild myalgia has often been reported by 5–10% of statin users [ 4 , 5 ], this rate reaching around 20% in a few reports [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of statin withdrawal on perceived and objective muscle function

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background and aims Statin-associated muscle symptoms (SAMS) are frequently reported. Nevertheless, few data on objective measures of muscle function are available. Recent data suggesting an important nocebo effect with statin use could confound such effects. The objective was to assess if subjective and objective measures of muscle function improve after drug withdrawal in SAMS reporters. Methods Patients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention composed three cohorts: statin users with (SAMS, n = 61) or without symptoms (No SAMS, n = 15), and controls (n = 16) (registered at clinicaltrials.gov, NCT01493648). Force (F), endurance (E) and power (P) of the leg extensors (ext) and flexors (fle) and handgrip strength (Fhg) were measured using isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale (VAS) was used to self-assess SAMS intensity. Measures were taken before and after two months of withdrawal. Results Following withdrawal, repeated-measures analyses show improvements for the entire cohort in Eext, Efle, Ffle, Pext and Pfle (range +7.2 to +13.3%, all p≤0.02). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to +16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS, from 5.09 to 1.85). Fhg was also improved in SAMS (+4.0 to +6.2%) when compared to No SAMS (-1.7 to -4.2%) (all p = 0.02). Conclusions Whether suffering from “true” SAMS or nocebo, those who reported SAMS had modest but relevant improvements in muscle function concurrent with a decrease in subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to muscle function in frail statin users appears warranted. Trial registration This study is registered in clinicaltrials.gov (NCT01493648).

show abstract

L’intolérance musculaire aux statines

Cited by 4 publications

References 32 publications

A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles

A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles

Impact of statin withdrawal on perceived and objective muscle function

Impact of statin withdrawal on perceived and objective muscle function

Contact Info

Product

Resources

About